Leukocyte Antigen (HLA) Class II Allele Frequencies in Female Patients with Breast Cancer: A Case Control Study
-
Ali-akbar Amirzargar
,
Majid Mahmoodi
,
Hedayat Nahvi
,
Mehdi Mahmoodi
,
Zahra Safari
,
Amir Kasaian
,
K Divsalar
,
Bijan Nahavandian
,
Abbas Jafari
,
Dariush Heydar-Nasab
,
Batool Moradi
,
Mohammad-Ali Mohagheghi
Abstract
Background: The study aimed to examine the association between human leukocyte antigen (HLA) class II allele frequencies and breast cancer in Iranian women.Methods: A total of 100 patients with pathologically proven breast cancer who referred to Cancer Institute were randomly selected and compared with a group of age matched healthy blood donors (n = 80). HLA class II alleles were determined by amplification of DNA followed by HLA-typing using sequence-specific primer (SSP) for each allele.Results: The frequency of HLA-DQA1*0301 (P=0.001, OR=3.4) and HLA-DRB1*1303 (P=0.02, OR=2.3) among breast cancer patients was significantly higher than those in control group. HLA-DQA1*0505 (P=0.003, OR=0.4), HLA-DRB1*1301 (P=0.002, OR=0.12) and HLA-DQA1*0101 (P=0.01, OR=0.21) alleles showed negative association with breast cancer.Conclusion: The findings suggest that HLA-DQA1*0301 allele is mainly associated with increased risk of breast cancer in Iranian female patients. HLA-DQA1*0505 and HLA-DRB1*1301 alleles are suggested as protective genetic factors against breast cancer. The findings confirm that specific alleles of HLA class II influence breast cancer risk.Forbes JF. The incidence of breast cancer: the global burden, public health considerations. Semin Oncol. 1997 Feb;24(1 Suppl 1):S1-20-S1-35.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108.
McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer- epidemiology, risk factors, and genetics. BMJ. 2000 Sep 9;321(7261):624-8.
Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science. 1994 Oct 7;266(5182):120-2.
Forbes SA, Trowsdale J. The MHC quarterly report. Immunogenetics. 1999 Nov;50(3-4):152-9.
Salih HR, Nussler V. Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance? Eur J Med Res. 2001 Aug 27;6(8):323-32.
Pistillo MP, Nicolo G, Salvi S, Capanni P, Perdelli L, Pasciucco G, et al. Biochemical analysis of HLA class I subunits expression in breast cancer tissues. Hum Immunol. 2000 Apr;61(4):397-407.
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002 Nov;3(11):991-8.
Chaudhuri S, Cariappa A, Tang M, Bell D, Haber DA, Isselbacher KJ, et al. Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles. Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11451-4.
Castro FA, Haimila K, Sareneva I, Schmitt M, Lorenzo J, Kunkel N, et al. Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population--a candidate gene approach. Int J Cancer. 2009 Oct 15;125(8):1851-8.
Hosono S, Kawase T, Matsuo K, Watanabe M, Kajiyama H, Hirose K, et al. HLA-A alleles and the risk of cervical squamous cell carcinoma in Japanese women. J Epidemiol. 2010;20(4):295-301.
Ishigami S, Natsugoe S, Nakajo A, Arigami T, Kitazono M, Okumura H, et al. HLA-class I expression in gastric cancer. J Surg Oncol. 2008 Jun 1;97(7):605-8.
Lee HW, Hahm KB, Lee JS, Ju YS, Lee KM, Lee KW. Association of the human leukocyte antigen class II alleles with chronic atrophic gastritis and gastric carcinoma in Koreans. J Dig Dis. 2009 Nov;10(4):265-71.
Gamzatova Z, Villabona L, van der Zanden H, Haasnoot GW, Andersson E, Kiessling R, et al. Analysis of HLA class I-II haplotype frequency and segregation in a cohort of patients with advanced stage ovarian cancer. Tissue Antigens. 2007 Sep;70(3):205- 13.
Gogas H, Kirkwood JM, Falk CS, Dafni U, Sondak VK, Tsoutsos D, et al. Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer. 2010 Sep 15;116(18):4326- 33.
Ghaderi A, Talei A, Gharesi-Fard B, Farjadian SH, Amirzargar A, Vasei M. HLA- DBR 1 alleles and the susceptibility of Iranian patients with breast cancer. Pathol Oncol Res. 2001;7(1):39-41.
Lavado R, Benavides M, Villar E, Ales I, Alonso A, Caballero A. The HLA-B7 allele confers susceptibility to breast cancer in Spanish women. Immunol Lett. 2005 Nov 15;101(2):223-5.
Cantu de Leon D, Perez-Montiel D, Villavicencio V, Garcia Carranca A, Mohar Betancourt A, Acuna-Alonzo V, et al. High resolution human leukocyte antigen (HLA) class I and class II allele typing in Mexican mestizo women with sporadic breast cancer: case-control study. BMC Cancer. 2009;9:48.
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988 Feb 11;16(3):1215.
Amirzargar AA, Yalda A, Hajabolbaghi M, Khosravi F, Jabbari H, Rezaei N, et al. The association of HLA-DRB, DQA1, DQB1 alleles and haplotype frequency in Iranian patients with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2004 Aug;8(8):1017-21.
Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence- specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens. 1992 May;39(5):225-35.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010 Jun 17.
Anderson BO, Jakesz R. Breast cancer issues in developing countries: an overview of the Breast Health Global Initiative. World J Surg. 2008 Dec;32(12):2578-85.
WHO. World Cancer Report WHO; 2008 [updated 2010]; Available from: http://www.iarc.fr/en/publications/pdfsonline/w cr/2008/index.php.
WHO. The Top 10 Causes of Death in 2004: World Health Organization2008.
Harirchi I, Kolahdoozan S, Karbakhsh M, Chegini N, Mohseni SM, Montazeri A, et al. Twenty years of breast cancer in Iran: downstaging without a formal screening program. Ann Oncol. 2011 Jan;22(1):93-7.
Harirchi I, Mousavi SM, Mohagheghi MA, Mousavi-Jarrahi A, Ebrahimi M, Montazeri A, et al. Early detection for breast cancer in iran. Asian Pac J Cancer Prev. 2009;10(5):849-51.
Baccar Harrath A, Yacoubi Loueslati B, Troudi W, Hmida S, Sedkaoui S, Dridi A, et al. HLA class II polymorphism: protective or risk factors to breast cancer in Tunisia? Pathol Oncol Res. 2006;12(2):79-81.
Ferrera A, Olivo A, Alaez C, Melchers WJ, Gorodezky C. HLA DOA1 and DOB1 loci in Honduran women with cervical dysplasia and invasive cervical carcinoma and their relationship to human papillomavirus infection. Hum Biol. 1999 Jun;71(3):367-79.
| Files | ||
| Issue | Vol 3 No 1 (2011) | |
| Section | Original Articles | |
| Keywords | ||
| Breast Cancer Human Leukocyte Antigen (HLA) Allele | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
